Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy

Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.

Richard J. Knox, Frank Friedlos, David Lydall et al. · PubMed · 1986 · 499 citations

Medicine, Oncology, Pharmacology +15

The Mechanism of Action of Antitumor Platinum Compounds

J. J. Roberts, Andrew J. Thomson · Progress in nucleic acid research and molecular biology · 1979 · 410 citations

Medicine, Medicinal Chemistry, Oncology +12

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

Duncan I. Jodrell, Merrill J. Egorin, Renzo Canetta et al. · Journal of Clinical Oncology · 1992 · 384 citations

Medicine, Oncology, Pharmacology +17

Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.

Merrill J. Egorin, David A. Van Echo, Stuart J. Tipping et al. · PubMed · 1984 · 306 citations

Pharmacy, Oncology, Pharmacology +17

Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

E Reed, Robert F. Ozols, Robert E. Tarone et al. · Proceedings of the National Academy of Sciences · 1987 · 220 citations · Full text

Medicine, Oncology, Pharmacology +15